电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

LYVE1 抗体 (Biotin)

This anti-LYVE1 antibody is a 兔 多克隆 antibody detecting LYVE1 in FACS. Suitable for 小鼠.
产品编号 ABIN1589714
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for LYVE1 抗体 (Biotin) (ABIN1589714)

抗原

See all LYVE1 抗体
LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

适用

  • 88
  • 64
  • 25
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
小鼠

宿主

  • 95
  • 7
  • 5
  • 1
  • 1

克隆类型

  • 83
  • 26
多克隆

标记

  • 57
  • 9
  • 5
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This LYVE1 antibody is conjugated to Biotin

应用范围

  • 82
  • 40
  • 29
  • 22
  • 15
  • 13
  • 12
  • 10
  • 9
  • 4
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS)
  • 特异性

    Recombinant mouse soluble LYVE-1

    产品特性

    Chromosomal location: 7, 7F2
    Produced from sera of rabbits immunised with highly pure recombinant mouse soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis). LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE 1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.

    纯化方法

    The antibody was purified via an antigen-affinity column and then biotinylated using a standard protocol.

    亚型

    IgG
  • 应用备注

    FACS: use 3-10 µg/mL

    说明

    Rabbit IG Polyclonal Antibody

    限制

    仅限研究用
  • 状态

    Lyophilized

    溶解方式

    Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

    缓冲液

    PBS, BSA (50x), 0.02 % sodium azide

    储存液

    Sodium azide

    注意事项

    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    注意事项

    Centrifuge vial prior to opening.

    储存条件

    -20 °C

    储存方法

    The lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8 °C. Frozen aliquots are stable for at least 6 months when stored at -20 °C.

    有效期

    6 months
  • 抗原

    LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

    别名

    Lyve-1

    背景

    LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41 % similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
    Synonyms: Lyve1, Xlkd1, Lyve-1, Crsbp-1, 1200012G08Rik

    NCBI登录号

    NP_444477, NM_053247

    UniProt

    Q8BHC0

    途径

    Glycosaminoglycan Metabolic Process
You are here: